Development asset linked to Shanghai Antengene Corporation in public FDA and regional records.
pharma · Relapsed/Refractory Diffuse Large B-cell Lymphoma · Non-muscle invasive bladder cancer (NMIBC)
Shanghai Antengene Corporation
Shanghai Antengene Corporation Limited
Shanghai Antengene Corporation drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
SAINT-LAURENT, CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- SAINT-LAURENT, CN
- Programs
- 3
- Drugs
- 8
- Patents
- 53
Shanghai Antengene Corporation pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Shanghai Antengene Corporation drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor agonist
-
insulin aspart
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
US regulatory status: approved.
-
selinexor
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Exportin-1.
- Target
- Exportin-1
- Mechanism
- Exportin-1 inhibitor
-
Development asset linked to Shanghai Antengene Corporation in public FDA and regional records.